Biosimilars are meant to be more affordable than the reference product. They are expected to help the U.S. healthcare system and consumers save money, but biosimilar products are still very expensive and unaffordable for most patients without insurance. According to the RAND Corporation, biosimilars...
Biosimilars are meant to be more affordable than the reference product. They are expected to help the U.S. healthcare system and consumers save money, but biosimilar products are still very expensive and unaffordable for most patients without insurance. According to the RAND Corporation, biosimilars...